Westend Capital Management’s DexCom DXCM Stock Holding History

Westend Capital Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-6	Closed	-$832	–	262
2024 Q1	$832	Buy	+6	New	+$754	﹤0.01%	280

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Westend Capital Management's DXCM Position: Q2 2024 in Review

Westend Capital Management sold out of DexCom (DXCM) in Q2 2024, closing a stake of 6 shares — an estimated $832 sold.

Westend Capital Management first reported a position in DXCM in Q1 2024 and held it in 1 quarter. The position peaked at $832 in Q1 2024. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Westend Capital Management reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Westend Capital Management sold 6 DexCom shares in Q2 2024, an estimated $832.
Westend Capital Management first reported a position in DexCom in Q1 2024 and held it in 1 quarter.
Westend Capital Management's DexCom position peaked at $832 in Q1 2024.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Westend Capital Management's 13F filing for Q2 2024, filed 8 Jul 2024.